(Q39443218)

12 September 2017

Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells (English)

1 reference

12 September 2017

0 references

1 reference

S M Manohar

1

1 reference

12 September 2017

A A Padgaonkar

2

1 reference

12 September 2017

A Jalota-Badhwar

3

1 reference

12 September 2017

S V Rao

4

1 reference

12 September 2017

K S Joshi

5

1 reference

12 September 2017

15 November 2011

1 reference

Prostate Cancer and Prostatic Diseases

12 September 2017

1 reference

12 September 2017

15

1 reference

12 September 2017

1

1 reference

12 September 2017

15-27

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2011.51

12 September 2017

0 references

cites work

YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Inhibitory effect of 6-formylpterin on HIF-1alpha protein accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Benzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Hsp90 inhibitors as novel cancer chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

HIF-1 as a target for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

New anticancer strategies targeting HIF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Hypoxia inducible factor-1: a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Molecularly targeted therapy for gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Role of hypoxia-inducible factor-1alpha as a cancer therapy target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

XQ2, a novel TPZ derivative, induced G2/M phase arrest and apoptosis under hypoxia in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Proliferation of human peripheral lymphocytes. Characteristics of cells once stimulated or re-stimulated by concanavalin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Hypoxia-Inducible Factor-1 Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

Glycobiology and cancer: meeting summary and future diections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.51

https://api.fatcat.wiki/v0/release/3znnjsrvofgmzbdwp3xaf6t5qe

31 March 2020

Identifiers

1 reference

mapped directly with Wikidata item

30 July 2022

based on heuristic

Dimensions Publication ID

1049988375

0 references

Fatcat ID

release_3znnjsrvofgmzbdwp3xaf6t5qe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3znnjsrvofgmzbdwp3xaf6t5qe

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/3znnjsrvofgmzbdwp3xaf6t5qe